What's new

Orphan designation: xevinapant Treatment of ovarian cancer, 11/11/2015 Withdrawn

Orphan designation: xevinapant Treatment of ovarian cancer, 11/11/2015 Withdrawn

Feb 20, 2025 - 15:10
 0
Orphan designation: xevinapant Treatment of ovarian cancer, 11/11/2015 Withdrawn
Orphan designation: xevinapant Treatment of ovarian cancer, 11/11/2015 Withdrawn
Read More

Tags:

Previous Article

Shortage of workshops capable of electric van MOT testing

Next Article

Orphan designation: Adeno-associated virus serotype 5 vector encoding C1-esteras...

Related Posts

Human medicines European public assessment report (EPAR): GoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.), budesonide,formoterol fumarate dihydrate, Date of authorisation: 03/04/2020, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025  0

First topical gene therapy treatment for dystrophic epidermolysis bullosa

First topical gene therapy treatment for dystrophic epi...

Feb 28, 2025  0

Clinical Trial Information System (CTIS) evaluation tim...

Feb 27, 2025  0